PremiumThe FlyAxsome Therapeutics price target raised to $162 from $160 at Baird Axsome Therapeutics price target raised to $165 from $160 at Wells Fargo Axsome Therapeutics: Strong Market Performance and Promising Growth Potential with Key Catalysts Ahead PremiumThe FlyAxsome Therapeutics reports Q1 EPS ($1.22), consensus ($1.35) Axsome Therapeutics expects cash to fund operations into cash flow positivity AXSM Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumStock Analysis & IdeasSeeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy William Blair healthcare analysts hold an analyst/industry conference call Promising Developments in Axsome Therapeutics’ AXS-12 Bolster Buy Rating